MyFinsight
Home
Blog
About
Bulk RHu PH20
$59,618K
Proprietary Products Sales
$55,428K
(19.32%↑ Y/Y)
Device Partnered
Products
$14,580K
(23.70%↑ Y/Y)
Upfront Fees
$35,500K
Event Based
Development And Regulatory...
$5,706K
(-76.71%↓ Y/Y)
Device Licensing And
Development
$2,468K
(-39.36%↓ Y/Y)
Royalty
$307,699K
(49.63%↑ Y/Y)
Product
$129,626K
(59.03%↑ Y/Y)
Collaborative Agreements
$43,674K
(13.23%↑ Y/Y)
Total revenues
$480,999K
(47.67%↑ Y/Y)
Operating income
$287,654K
(42.09%↑ Y/Y)
Investment and other
income, net
$2,836K
(-58.84%↓ Y/Y)
Total operating
expenses
$193,345K
(56.84%↑ Y/Y)
Income before income
tax expense
$284,902K
(39.02%↑ Y/Y)
Interest expense
$5,588K
(27.17%↑ Y/Y)
Cost of sales
$79,171K
(70.78%↑ Y/Y)
Selling, general and
administrative
$56,998K
(36.97%↑ Y/Y)
Amortization of intangibles
$29,512K
(66.15%↑ Y/Y)
Research and development
$27,664K
(57.69%↑ Y/Y)
Net income
$229,913K
(39.21%↑ Y/Y)
Income tax expense
$54,989K
(38.24%↑ Y/Y)
Back
Back
Income Statement
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)
source: myfinsight.com